Financings in Brief: Med-Design Corporation
This article was originally published in The Gray Sheet
Executive Summary
Med-Design Corporation: Files registration statement with the Securities and Exchange Commission for an initial public offering of 1.5 mil. shares of common stock, expected to be sold for between $6.50 and $7 per share. Based in Philadelphia, Med-Design is developing safety devices intended to lower the incidence of accidental needlesticks. The firm's first three products are a safety syringe, a safety phlebotomy set, and a safety catheter. Each product features a retractable needle that is rendered risk-free once therapy is delivered. The 11-employee company anticipates that FDA will determine all three products to be Class II devices and that 510(k)s for all three will be filed by the end of 1995.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.